Abstract:Abstract: Giant cell arteritis (GCA) is a systemic granulomatous vasculitis affecting the medium and large-size arteries, and may present with a range of ophthalmic findings. This review will cover GCA epidemiology, pathophysiology, clinical presentation, diagnostic workup, and treatment. Epidemiology and pathophysiology: GCA is commonly found in elderly patients and individuals of Scandinavian descent. Recent publications suggest it may be more common in African Americans and Hispanics than previously thought. It is very rare in Asian and Middle-Eastern populations, and there is little data regarding African populations. Genetic studies have identified increased risk associated with HLA-DRB1*04. Rather than a response to a specific antigen such as varicella zoster virus, current immunology research suggests that GCA results from changes associated with the aging immune system. Clinical presentation to ophthalmology: Arteritic anterior ischemic optic neuropathy is the most common ophthalmic manifestation of GCA, but central or branch retinal artery occlusion, ophthalmic artery occlusion, cranial neuropathies causing diplopia, and more rarely anterior segment ischemia and anisocoria may also occur. Clinical testing including visual field testing, OCT, OCT-A, ICG and fluorescein angiography can be helpful in suggesting a diagnosis in addition to the clinical exam. Diagnostic workup: GCA is ultimately a clinical diagnosis, but it is usually supported with lab results, pathology, and/or imaging. Temporal artery biopsy (TAB) remains the gold standard diagnostic test although its sensitivity is debated and practice patterns still vary with respect to sample length and whether unilateral or simultaneous bilateral biopsies are performed. Some studies have reported higher sensitivity of ultrasounds over TAB, with added benefits of time efficiency and cost effectiveness, promoting the diagnostic use of ultrasounds. MRI and even PET CT protocols offer additional options for less invasive diagnostic testing. Treatment: Vision-threatening GCA is treated acutely with emergent admission for intravenous methylprednisolone, and long-term high dose oral corticosteroids remain the standard of care, despite common and sometimes serious side effects. The use of steroid-sparing alternatives such as tocilizumab is becoming more common and additional agents are being investigated.

Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders

Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Aging of the Vascular System and Neural Diseases

Endothelial C3a Receptor Mediates Vascular Inflammation and Blood-Brain Barrier Permeability During Aging

Age-Related Impairment Of Vascular Structure And Functions

Age-related Cerebral Small Vessel Disease and Inflammaging

The Role of Immunosenescence in Cerebral Small Vessel Disease: A Review

Impact of Aging on Cardiovascular Diseases

Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice

Update of Immunosenescence in Cerebral Small Vessel Disease

Vascular Contributions to Healthy Aging and Dementia

Immunoinhibitory Checkpoint Deficiency in Medium and Large Vessel Vasculitis

Angiogenesis, Cancer, and Vascular Aging

Vasculitogenic T Cells in Large Vessel Vasculitis

Inflammation, apoptosis and autophagy as critical players in vascular dementia

The diagnosis and treatment of giant cell arteritis

Giant Cell Arteritis: Updates and Controversies

Vascular disease persistence in giant cell arteritis: are stromal cells neglected?

Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways

INCREASED C3 IN THE AGING BRAIN PROMOTES INFLAMMATORY TRANSITION IN ENDOTHELIAL CELLS

T-Cell Aging-Associated Phenotypes in Autoimmune Disease